Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Opko Health (0KCS) Share Price & Analysis

1 Followers

0KCS Stock Chart & Stats

$1.70$0.05(3.09%)
At close: 4:30 PM GMT
$1.4$1.6$1.8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.70 - $1.74
52-Week Range
$0.98 - $1.86
Previous Close
$1.65
Volume
N/A
Average Volume (3M)
74.56K
Market Cap
$1.27B
Enterprise Value
$1.33B
Total Cash (Recent Filing)
$390.22M
Total Debt (Recent Filing)
$514.09M
Price to Earnings (P/E)
―
Beta
1.00
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.06
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strategic Repositioning

The planned divestiture can provide substantial liquidity while moving OPKO away from clinical laboratory services and toward Innovative Biotech and Global Products. A more focused portfolio may simplify operations, concentrate investment on higher-potential programs, and create additional long-term royalty participation.

Global Products Growth

Growth in product revenue combined with a shift to positive segment operating income indicates improving economics in an ongoing business. Continued Rayaldee growth, international operations, and commercial products could provide a more dependable base to offset volatility from development-stage programs.

Manageable Leverage

The relatively modest debt burden and substantial equity base provide balance-sheet support as OPKO funds commercialization and clinical development. Lower leverage can preserve financial flexibility for strategic investment and reduce the immediate pressure that debt service would place on already challenged operating results.

Bears Say

Shrinking Revenue And Persistent Losses

The continuing revenue contraction and negative operating and net margins show that OPKO has not yet established durable earnings power. Persistent losses reduce internally generated funding for product launches and research, while the multiyear decline increases the importance of successful portfolio repositioning.

Divestiture Execution Risk

The strategic transition depends on a transaction that has not yet closed, creating execution and timing risk over the coming quarters. Approval requirements and substantial sale-related costs could delay the intended portfolio reset, consume liquidity, and temporarily obscure the underlying performance of continuing operations.

Biotech Losses And Higher R&D

Increasing investment in early-stage programs can support future pipeline value, but it is currently widening losses without corresponding commercial revenue. Continued spending raises the funding burden and leaves results dependent on clinical progress, regulatory advancement, and eventual product commercialization.

Opko Health News

0KCS FAQ

What was Opko Health’s price range in the past 12 months?
Opko Health lowest share price was $0.98 and its highest was $1.86 in the past 12 months.
What is Opko Health’s market cap?
Opko Health’s market cap is $1.27B.
When is Opko Health’s upcoming earnings report date?
Opko Health’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 111 days.
How were Opko Health’s earnings last quarter?
Opko Health released its earnings results on Nov 04, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.018.
Is Opko Health overvalued?
According to Wall Street analysts Opko Health’s price is currently Undervalued.
Does Opko Health pay dividends?
Opko Health does not currently pay dividends.
What is Opko Health’s EPS estimate?
Opko Health’s EPS estimate is -0.06.
How many shares outstanding does Opko Health have?
Opko Health has 742,506,500 shares outstanding.
What happened to Opko Health’s price movement after its last earnings report?
Opko Health reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went down -4.494%.
Which hedge fund is a major shareholder of Opko Health?
Hedge funds hold Opko Health shares: the largest hedge-fund position in Opko Health is 835,469,037 shares, and hedge funds increased their holdings by 3.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology